Masimo (NASDAQ:MASI) Releases FY25 Earnings Guidance

Masimo (NASDAQ:MASI) updated its FY25 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $4.90-$5.10 for the period, compared to the consensus estimate of $4.74.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Wells Fargo & Company lifted their price target on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 target price (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Raymond James boosted their price target on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Finally, Piper Sandler boosted their target price on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Masimo has a consensus rating of “Moderate Buy” and a consensus price target of $179.67.

Masimo Trading Up 3.6 %

MASI opened at $172.07 on Thursday. Masimo has a one year low of $101.61 and a one year high of $180.97. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The business has a 50 day simple moving average of $168.86 and a two-hundred day simple moving average of $139.54. The firm has a market capitalization of $9.21 billion, a price-to-earnings ratio of 118.67 and a beta of 1.01.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. During the same quarter in the previous year, the firm posted $0.63 EPS. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Analysts predict that Masimo will post 4.03 EPS for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.